Paradigm Biopharmaceuticals (ASX:PAR) appointed Daniel Furtner as its Chief Medical Officer, effective Wednesday, according to a Tuesday Australian bourse filing.
Furtner succeeds Donna Skerrett, who will remain with the firm as a senior scientific advisor.
Furtner previously served as the senior director of medical affairs for the Asia Pacific region at CSL.
Its shares fell 2% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.